Challenging the preclinical paradigm: Adverse effects of antiseizure medicines in male rats with drug‐resistant epilepsy
British Journal of Pharmacology · 2025
DOI: 10.1111/bph.70076 ↗At a glance
Journal article in British Journal of Pharmacology, 2025. Written by Michelle Guignet and 4 co-authors. Institution: Center for Epilepsy Drug Discovery, Department of Pharmacy, School of Pharmacy, University of Washington, Seattle, WA, USA. Major MEDLINE topics: Anticonvulsants, Drug Resistant Epilepsy, Carbamazepine. Cited 2 times so far (Crossref); 45 references. Funded by: UW School of Pharmacy, NCATS NIH HHS, Department of Pharmacy.
Abstract (original language)
Background and Purpose Drug‐resistant epilepsy affects 30% of patients who have uncontrolled seizures despite current antiseizure medications (ASMs). Preclinical drug screening often uses acute dosing and evoked seizures, which may not fully capture the complexities of drug resistance and human treatment regimens. We introduce a novel experimental paradigm that incorporates clinical treatment regimens, pharmacokinetic monitoring and behavioural tolerability assessments to accurately model drug‐resistant epilepsy in animal models. Experimental Approach Rats with epilepsy following kainic acid‐induced status epilepticus were enrolled in a triple cross‐over study to evaluate the dose‐dependent efficacy and tolerability of three commonly used ASMs: ‐ lamotrigine, levetiracetam and carbamazepine. Each medication was delivered in rodent chow for 2 weeks via our automated system, maintaining steady‐state exposures measured by pharmacokinetic sampling. Seizure control was monitored via 24/7 videoEEG and behavioural tolerability was evaluated using minimal motor impairment and hyperexcitability assays. Key Results Chronic oral dosing with carbamazepine and levetiracetam reduced seizure frequency by more than 50% in over half the animals at clinically relevant doses. Lamotrigine, however, was either ineffective or worsened seizures at toxic doses, increasing both convulsive and clustered seizures. Levetiracetam was well tolerated, while carbamazepine impaired motor function at the highest dose. Lamotrigine led to increased hyperactivity and aggressive behaviour at all doses. Conclusion and Implications This study highlights the need for preclinical models that better reflect human epilepsy, considering both efficacy and side effects in drug development. Our findings emphasize the complexity of drug responses and underscore the importance of improved models for drug development.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Center for Epilepsy Drug Discovery, Department of Pharmacy, School of Pharmacy, University of Washington, Seattle, WA, USA.
ORCID profiles: Michelle Guignet
Funding
- UW School of Pharmacy
- NCATS NIH HHS
- Department of Pharmacy
- American Epilepsy Society
- National Center for Advancing Translational Sciences
Cite
APA
Guignet, M., Vuong, J., Uribe, N., Ballapapinan, T., & White, H. S. (2025). Challenging the preclinical paradigm: Adverse effects of antiseizure medicines in male rats with drug‐resistant epilepsy. British Journal of Pharmacology. https://doi.org/10.1111/bph.70076
Vancouver
Guignet M, Vuong J, Uribe N, Ballapapinan T, White HS. Challenging the preclinical paradigm: Adverse effects of antiseizure medicines in male rats with drug‐resistant epilepsy. British Journal of Pharmacology. 2025. doi:10.1111/bph.70076
BibTeX
@article{Guignet2025,
author = {Guignet, Michelle and Vuong, Jonathan and Uribe, Nicholas and Ballapapinan, Ticha and White, H Steve},
title = {Challenging the preclinical paradigm: Adverse effects of antiseizure medicines in male rats with drug‐resistant epilepsy},
journal = {British Journal of Pharmacology},
year = {2025},
doi = {10.1111/bph.70076}
}
EUVIMED